Patrick Royston
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Patrick Royston has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
- Mahesh K. B. Parmar
MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London, UK
6 shared publications - Babak Choodari-Oskooei
MRC Clinical Trials Unit at UCL London UK
3 shared publications - Ian R. White
Affiliation MRC Clinical Trials Unit at University College London, London, United Kingdom
3 shared publications - Yinghui Wei
Faculty of Health and Life Sciences, University of Exeter, Exeter, UK
3 shared publications - Abdel G. Babiker
MRC Clinical Trials Unit, University College London, London, U.K.
2 shared publications - Ella Marley-Zagar
MRC Clinical Trials Unit, University College London, London, U.K.
2 shared publications
Latest Publications
- 20 June 2025
- Published by Springer Nature
- p. 1609-1616
Multivariable Fractional Polynomial Models and Extensions
- 20 June 2025
- Published by Springer Nature
- p. 1609-1616
Multivariable Fractional Polynomial Models and Extensions
- Open Access
- 5 April 2023
- Published by SAGE Publications in The Stata Journal: Promoting communications on statistics and Stata
- Vol. 23 (1) , 24-52
artbin: Extended sample size for randomized trials with binary outcomes
We describe the command artbin, which offers various new facilities for the calculation of sample size for binary outcome variables that are not otherwise available in Stata. While artbin has been available since 2004, it has not been previously described in the Stata Journal. artbin has been recently updated to include new options for different statistical tests, methods and study designs, improved syntax, and better handling of noninferiority trials. In this article, we describe the updated version of artbin and detail the various formulas used within artbin in different settings.
- 5 April 2023
- Published by SAGE Publications in The Stata Journal: Promoting communications on statistics and Stata
- Vol. 23 (1) , 24-52
Open Accessartbin: Extended sample size for randomized trials with binary outcomes
We describe the command artbin, which offers various new facilities for the calculation of sample size for binary outcome variables that are not otherwise available in Stata. While artbin has been available since 2004, it has not been previously described in the Stata Journal. artbin has been recently updated to include new options for different statistical tests, methods and study designs, improved syntax, and better handling of noninferiority trials. In this article, we describe the updated version of artbin and detail the various formulas used within artbin in different settings.
- Open Access
- 1 March 2023
- Published by SAGE Publications in The Stata Journal: Promoting communications on statistics and Stata
- Vol. 23 (1) , 3-23
artcat: Sample-size calculation for an ordered categorical outcome
We describe a new command, artcat, that calculates sample size or power for a randomized controlled trial or similar experiment with an ordered categorical outcome, where analysis is by the proportional-odds model. artcat implements the method of Whitehead (1993, Statistics in Medicine 12: 2257–2271). We also propose and implement a new method that 1) allows the user to specify a treatment effect that does not obey the proportional-odds assumption, 2) offers greater accuracy for large treatment effects, and 3) allows for noninferiority trials. We illustrate the command and explore the value of an ordered categorical outcome over a binary outcome in various settings. We show by simulation that the methods perform well and that the new method is more accurate than Whitehead’s method.
- 1 March 2023
- Published by SAGE Publications in The Stata Journal: Promoting communications on statistics and Stata
- Vol. 23 (1) , 3-23
Open Accessartcat: Sample-size calculation for an ordered categorical outcome
We describe a new command, artcat, that calculates sample size or power for a randomized controlled trial or similar experiment with an ordered categorical outcome, where analysis is by the proportional-odds model. artcat implements the method of Whitehead (1993, Statistics in Medicine 12: 2257–2271). We also propose and implement a new method that 1) allows the user to specify a treatment effect that does not obey the proportional-odds assumption, 2) offers greater accuracy for large treatment effects, and 3) allows for noninferiority trials. We illustrate the command and explore the value of an ordered categorical outcome over a binary outcome in various settings. We show by simulation that the methods perform well and that the new method is more accurate than Whitehead’s method.
- 20 January 2023
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 41 (3) , 704-706
Reply to U. Capitanio et al
- 20 January 2023
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 41 (3) , 704-706
Reply to U. Capitanio et al
- 20 July 2022
- Published by Springer Nature
- p. 1507-1542
Multi-arm Multi-stage (MAMS) Platform Randomized Clinical Trials
- 20 July 2022
- Published by Springer Nature
- p. 1507-1542
Multi-arm Multi-stage (MAMS) Platform Randomized Clinical Trials
- Open Access
- 6 April 2020
- Published by Springer Nature in Trials
- Vol. 21 (1) , 1-17
A simulation study comparing the power of nine tests of the treatment effect in randomized controlled trials with a time-to-event outcome
Background: The logrank test is routinely applied to design and analyse randomized controlled trials (RCTs) with time-to-event outcomes. Sample size and power calculations assume the treatment effect follows proportional hazards (PH). If the PH assumption is false, power is reduced and interpretation of the hazard ratio (HR) as the estimated treatment effect is compromised. Using statistical simulation, we investigated the type 1 error and power of the logrank (LR)test and eight alternatives. We aimed to identify test(s) that improve power with three types of non-proportional hazards (non-PH): early, late or near-PH treatment effects. Methods: We investigated weighted logrank tests (early, LRE; late, LRL), the supremum logrank test (SupLR) and composite tests (joint, J; combined, C; weighted combined, WC; versatile and modified versatile weighted logrank, VWLR, VWLR2) with two or more components. Weighted logrank tests are intended to be sensitive to particular non-PH patterns. Composite tests attempt to improve power across a wider range of non-PH patterns. Using extensive simulations based on real trials, we studied test size and power under PH and under simple departures from PH comprising pointwise constant HRs with a single change point at various follow-up times. We systematically investigated the influence of high or low control-arm event rates on power. Results: With no preconceived type of treatment effect, the preferred test is VWLR2. Expecting an early effect, tests with acceptable power are SupLR, C, VWLR2, J, LRE and WC. Expecting a late effect, acceptable tests are LRL, VWLR, VWLR2, WC and J. Under near-PH, acceptable tests are LR, LRE, VWLR, C, VWLR2 and SupLR. Type 1 error was well controlled for all tests, showing only minor deviations from the nominal 5%. The location of the HR change point relative to the cumulative proportion of control-arm events considerably affected power. Conclusions: Assuming ignorance of the likely treatment effect, the best choice is VWLR2. Several non-standard tests performed well when the correct type of treatment effect was assumed. A low control-arm event rate reduced the power of weighted logrank tests targeting early effects. Test size was generally well controlled. Further investigation of test characteristics with different types of non-proportional hazards of the treatment effect is warranted.
- 6 April 2020
- Published by Springer Nature in Trials
- Vol. 21 (1) , 1-17
Open AccessA simulation study comparing the power of nine tests of the treatment effect in randomized controlled trials with a time-to-event outcome
Background: The logrank test is routinely applied to design and analyse randomized controlled trials (RCTs) with time-to-event outcomes. Sample size and power calculations assume the treatment effect follows proportional hazards (PH). If the PH assumption is false, power is reduced and interpretation of the hazard ratio (HR) as the estimated treatment effect is compromised. Using statistical simulation, we investigated the type 1 error and power of the logrank (LR)test and eight alternatives. We aimed to identify test(s) that improve power with three types of non-proportional hazards (non-PH): early, late or near-PH treatment effects. Methods: We investigated weighted logrank tests (early, LRE; late, LRL), the supremum logrank test (SupLR) and composite tests (joint, J; combined, C; weighted combined, WC; versatile and modified versatile weighted logrank, VWLR, VWLR2) with two or more components. Weighted logrank tests are intended to be sensitive to particular non-PH patterns. Composite tests attempt to improve power across a wider range of non-PH patterns. Using extensive simulations based on real trials, we studied test size and power under PH and under simple departures from PH comprising pointwise constant HRs with a single change point at various follow-up times. We systematically investigated the influence of high or low control-arm event rates on power. Results: With no preconceived type of treatment effect, the preferred test is VWLR2. Expecting an early effect, tests with acceptable power are SupLR, C, VWLR2, J, LRE and WC. Expecting a late effect, acceptable tests are LRL, VWLR, VWLR2, WC and J. Under near-PH, acceptable tests are LR, LRE, VWLR, C, VWLR2 and SupLR. Type 1 error was well controlled for all tests, showing only minor deviations from the nominal 5%. The location of the HR change point relative to the cumulative proportion of control-arm events considerably affected power. Conclusions: Assuming ignorance of the likely treatment effect, the best choice is VWLR2. Several non-standard tests performed well when the correct type of treatment effect was assumed. A low control-arm event rate reduced the power of weighted logrank tests targeting early effects. Test size was generally well controlled. Further investigation of test characteristics with different types of non-proportional hazards of the treatment effect is warranted.
- Open Access
- 18 March 2019
- Published by Springer Nature in Trials
- Vol. 20 (1) , 172
Combined test versus logrank/Cox test in 50 randomised trials
The logrank test and the Cox proportional hazards model are routinely applied in the design and analysis of randomised controlled trials (RCTs) with time-to-event outcomes. Usually, sample size and power calculations assume proportional hazards (PH) of the treatment effect, i.e. the hazard ratio is constant over the entire follow-up period. If the PH assumption fails, the power of the logrank/Cox test may be reduced, sometimes severely. It is, therefore, important to understand how serious this can become in real trials, and for a proven, alternative test to be available to increase the robustness of the primary test. We performed a systematic search to identify relevant articles in four leading medical journals that publish results of phase 3 clinical trials. Altogether, 50 articles satisfied our inclusion criteria. We digitised published Kaplan–Meier curves and created approximations to the original times to event or censoring at the individual patient level. Using the reconstructed data, we tested for non-PH in all 50 trials. We compared the results from the logrank/Cox test with those from the combined test recently proposed by Royston and Parmar. The PH assumption was checked and reported only in 28% of the studies. Evidence of non-PH at the 0.10 level was detected in 31% of comparisons. The Cox test of the treatment effect was significant at the 0.05 level in 49% of comparisons, and the combined test in 55%. In four of five trials with discordant results, the interpretation would have changed had the combined test been used. The degree of non-PH and the dominance of the p value for the combined test were strongly associated. Graphical investigation suggested that non-PH was mostly due to a treatment effect manifesting in an early follow-up and disappearing later. The evidence for non-PH is checked (and, hence, identified) in only a small minority of RCTs, but non-PH may be present in a substantial fraction of such trials. In our reanalysis of the reconstructed data from 50 trials, the combined test outperformed the Cox test overall. The combined test is a promising approach to making trial design and analysis more robust.
- 18 March 2019
- Published by Springer Nature in Trials
- Vol. 20 (1) , 172
Open AccessCombined test versus logrank/Cox test in 50 randomised trials
The logrank test and the Cox proportional hazards model are routinely applied in the design and analysis of randomised controlled trials (RCTs) with time-to-event outcomes. Usually, sample size and power calculations assume proportional hazards (PH) of the treatment effect, i.e. the hazard ratio is constant over the entire follow-up period. If the PH assumption fails, the power of the logrank/Cox test may be reduced, sometimes severely. It is, therefore, important to understand how serious this can become in real trials, and for a proven, alternative test to be available to increase the robustness of the primary test. We performed a systematic search to identify relevant articles in four leading medical journals that publish results of phase 3 clinical trials. Altogether, 50 articles satisfied our inclusion criteria. We digitised published Kaplan–Meier curves and created approximations to the original times to event or censoring at the individual patient level. Using the reconstructed data, we tested for non-PH in all 50 trials. We compared the results from the logrank/Cox test with those from the combined test recently proposed by Royston and Parmar. The PH assumption was checked and reported only in 28% of the studies. Evidence of non-PH at the 0.10 level was detected in 31% of comparisons. The Cox test of the treatment effect was significant at the 0.05 level in 49% of comparisons, and the combined test in 55%. In four of five trials with discordant results, the interpretation would have changed had the combined test been used. The degree of non-PH and the dominance of the p value for the combined test were strongly associated. Graphical investigation suggested that non-PH was mostly due to a treatment effect manifesting in an early follow-up and disappearing later. The evidence for non-PH is checked (and, hence, identified) in only a small minority of RCTs, but non-PH may be present in a substantial fraction of such trials. In our reanalysis of the reconstructed data from 50 trials, the combined test outperformed the Cox test overall. The combined test is a promising approach to making trial design and analysis more robust.
- Open Access
- 1 December 2018
- Published by SAGE Publications in The Stata Journal: Promoting communications on statistics and Stata
- Vol. 18 (4) , 995-996
Power and Sample-Size Analysis for the Royston–Parmar Combined Test in Clinical Trials with a Time-to-Event Outcome: Correction and Program Update
The changes made to Royston (2018) and to power_ct are i) in section 2.4 (Sample-size calculation for the combined test), to replace ordinary least-squares (OLS) regression using regress with grouped probit regression using glm; ii) in section 4 (Examples), to revisit the worked examples of sample-size estimation in light of the revised estimation procedure; and iii) to update the help file entry for the option n(numlist). The updated software is version 1.2.0.
- 1 December 2018
- Published by SAGE Publications in The Stata Journal: Promoting communications on statistics and Stata
- Vol. 18 (4) , 995-996
Open AccessPower and Sample-Size Analysis for the Royston–Parmar Combined Test in Clinical Trials with a Time-to-Event Outcome: Correction and Program Update
The changes made to Royston (2018) and to power_ct are i) in section 2.4 (Sample-size calculation for the combined test), to replace ordinary least-squares (OLS) regression using regress with grouped probit regression using glm; ii) in section 4 (Examples), to revisit the worked examples of sample-size estimation in light of the revised estimation procedure; and iii) to update the help file entry for the option n(numlist). The updated software is version 1.2.0.
- 1 March 2018
- Published by SAGE Publications in The Stata Journal: Promoting communications on statistics and Stata
- Vol. 18 (1) , 3-21
Power and sample-size analysis for the Royston–Parmar combined test in clinical trials with a time-to-event outcome
Randomized controlled trials with a time-to-event outcome are usually designed and analyzed assuming proportional hazards (PH) of the treatment effect. The sample-size calculation is based on a log-rank test or the nearly identical Cox test, henceforth called the Cox/log-rank test. Nonproportional hazards (non-PH) has become more common in trials and is recognized as a potential threat to interpreting the trial treatment effect and the power of the log-rank test—hence to the success of the trial. To address the issue, in 2016, Royston and Parmar (BMC Medical Research Methodology 16: 16) proposed a “combined test” of the global null hypothesis of identical survival curves in each trial arm. The Cox/log-rank test is combined with a new test derived from the maximal standardized difference in restricted mean survival time (RMST) between the trial arms. The test statistic is based on evaluations of the between-arm difference in RMST over several preselected time points. The combined test involves the minimum p-value across the Cox/log-rank and RMST-based tests, appropriately standardized to have the correct distribution under the global null hypothesis. In this article, I introduce a new command, power_ct, that uses simulation to implement power and sample-size calculations for the combined test. power_ct supports designs with PH or non-PH of the treatment effect. I provide examples in which the power of the combined test is compared with that of the Cox/log-rank test under PH and non-PH scenarios. I conclude by offering guidance for sample-size calculations in time-to-event trials to allow for possible non-PH.
- 1 March 2018
- Published by SAGE Publications in The Stata Journal: Promoting communications on statistics and Stata
- Vol. 18 (1) , 3-21
Power and sample-size analysis for the Royston–Parmar combined test in clinical trials with a time-to-event outcome
Randomized controlled trials with a time-to-event outcome are usually designed and analyzed assuming proportional hazards (PH) of the treatment effect. The sample-size calculation is based on a log-rank test or the nearly identical Cox test, henceforth called the Cox/log-rank test. Nonproportional hazards (non-PH) has become more common in trials and is recognized as a potential threat to interpreting the trial treatment effect and the power of the log-rank test—hence to the success of the trial. To address the issue, in 2016, Royston and Parmar (BMC Medical Research Methodology 16: 16) proposed a “combined test” of the global null hypothesis of identical survival curves in each trial arm. The Cox/log-rank test is combined with a new test derived from the maximal standardized difference in restricted mean survival time (RMST) between the trial arms. The test statistic is based on evaluations of the between-arm difference in RMST over several preselected time points. The combined test involves the minimum p-value across the Cox/log-rank and RMST-based tests, appropriately standardized to have the correct distribution under the global null hypothesis. In this article, I introduce a new command, power_ct, that uses simulation to implement power and sample-size calculations for the combined test. power_ct supports designs with PH or non-PH of the treatment effect. I provide examples in which the power of the combined test is compared with that of the Cox/log-rank test under PH and non-PH scenarios. I conclude by offering guidance for sample-size calculations in time-to-event trials to allow for possible non-PH.
- Open Access
- 1 December 2017
- Published by SAGE Publications in The Stata Journal: Promoting communications on statistics and Stata
- Vol. 17 (4) , 786-802
Reconstructing Time-to-event Data from Published Kaplan–Meier Curves
Hazard ratios can be approximated by data extracted from published Kaplan–Meier curves. Recently, this curve approach has been extended beyond hazard-ratio approximation with the capability of constructing time-to-event data at the individual level. In this article, we introduce a command, ipdfc, to implement the reconstruction method to convert Kaplan–Meier curves to time-to-event data. We give examples to illustrate how to use the command.
- 1 December 2017
- Published by SAGE Publications in The Stata Journal: Promoting communications on statistics and Stata
- Vol. 17 (4) , 786-802
Open AccessReconstructing Time-to-event Data from Published Kaplan–Meier Curves
Hazard ratios can be approximated by data extracted from published Kaplan–Meier curves. Recently, this curve approach has been extended beyond hazard-ratio approximation with the capability of constructing time-to-event data at the individual level. In this article, we introduce a command, ipdfc, to implement the reconstruction method to convert Kaplan–Meier curves to time-to-event data. We give examples to illustrate how to use the command.